Artivion, Inc. (NYSE:AORT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Artivion, Inc. (NYSE:AORT) has been given an average rating of “Moderate Buy” by the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $46.1667.

AORT has been the topic of a number of recent research reports. Weiss Ratings lowered Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, June 8th. Stifel Nicolaus set a $45.00 price objective on Artivion in a research report on Monday, June 1st. LADENBURG THALM/SH SH upgraded shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a research note on Friday, April 10th. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Needham & Company LLC lowered their target price on shares of Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 8th.

Artivion Stock Up 4.4%

Artivion stock opened at $20.98 on Thursday. Artivion has a twelve month low of $19.16 and a twelve month high of $48.25. The stock’s fifty day simple moving average is $28.66 and its 200-day simple moving average is $36.79. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $1.02 billion, a P/E ratio of 87.42 and a beta of 1.27.

Insider Activity at Artivion

In related news, SVP Andrew M. Green sold 44,001 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the transaction, the senior vice president owned 60,259 shares in the company, valued at approximately $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Hedge Funds Weigh In On Artivion

A number of institutional investors and hedge funds have recently modified their holdings of the company. Verition Fund Management LLC grew its stake in shares of Artivion by 1.6% during the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock worth $716,000 after purchasing an additional 274 shares in the last quarter. Entropy Technologies LP grew its stake in shares of Artivion by 6.0% during the fourth quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock worth $251,000 after purchasing an additional 310 shares in the last quarter. Rockefeller Capital Management L.P. grew its stake in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Artivion by 6.2% during the third quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock worth $349,000 after purchasing an additional 477 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in shares of Artivion by 4.6% during the fourth quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock worth $512,000 after purchasing an additional 494 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.